Synthetic mammography performed equally as well to digital mammography with less radiation exposure.
Synthetic digital mammography images could be the next step in breast imaging, taking the place of digital mammography and improving patient experience, according to newly released study.
In a Sept. 23 article published in the American Journal of Roentgenology, a team from Canada shared the results of a review study that showed synthetic images re-produced from digital breast tomosynthesis scans have the same level of accuracy as those captured with traditional digital mammography.
Digital breast tomosynthesis has gained traction in recent years thanks to the growing body of evidence around its reduced recall and improved cancer detection rates. However, its use with traditional digital mammography also increases radiation exposure, said lead study author Peri Abdullah, Ph.D. Incorporating synthetic images instead could eliminate that added dose, Abdullah's team said.
“Reconstructing a synthetic image does not require additional radiation exposure beyond that required for digital breast tomosynthesis, which is not the case if digital mammography also has to be performed for the same patient,” the team wrote. “This is of concern when considering the risk of radiation-induced cancers, which may be higher with increased cumulative radiation doses.”
Related Content: Pairing DBT with Automated Breast Density Measurements Leads to Fewer Recalls
To determine the accuracy of synthetic images, Abdullah’s team analyzed 13 existing studies that examined patients who received synthesized 2D mammograms and conventional digital mammograms with or without additional digital breast tomosynthesis. All total, the studies included 201,304 patients.
According to their review, the team determined there was no significant difference in sensitivity or specificity between digital mammography and synthetic mammography either as stand-alone imaging techniques or in concert with digital breast tomosynthesis. And, they found, adjusting for bias, design, or reference standard did not make a difference.
In an accompanying editorial, Reni Butler, M.D., a breast imaging specialist and associate professor of radiology and biomedical imaging at Yale University School of Medicine, said these results indicate that using one scan for both 3D and 2D imaging is a possibility.
“This study supports utilization of digital breast tomosynthesis as a single acquisition-examination,” she said, “without a second radiation exposure to obtain a conventional 2D digital mammography.”
According to Abdullah’s team, the existing research indicates radiation dose drops by approximately half when providers use synthetic 2D images with digital breast tomosynthesis rather than digital mammography. This finding, they said, bolsters greater use of synthetic images.
But, the use of synthetic images still faces challenges, said Yale’s Butler. Some providers are still concerned that these re-produced images might have decreased sensitivity for fine micro-calcifications, subtle masses, and artificial pseudo-calcifications. But, some changes to daily practice, such as continuing to use traditional digital mammography for baseline screenings or capturing magnification views of micro-calcifications, could improve providers’ comfort level with using synthetic images.
“With minor adjustments to imaging protocols and reading patterns, these justifiable concerns can be largely overcome,” Butler said. “With these adaptations, the learning curve for incorporating synthetic mammography into clinical practice and achieving an acceptable level of comfort with it can be reasonably short.”
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.